Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Rethinking paracorporeal lung assist device support in the modern era: Why so different than ECMO?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Kidney and blood pressure sequelae after pediatric extracorporeal membrane oxygenation: a secondary analysis of the Kidney Injury During Membrane Oxygenation pediatric ECMO cohort.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Endocrine Effects of Arginine-Vasopressin After Pediatric Cardiac Surgery.

Pediatric cardiology·2025
Same author

Increased utilisation of analgesia and sedation in patients following bidirectional Glenn: evidence for the "Glenn Headache"?

Cardiology in the young·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Subclinical thyroid disease.

David S Cooper1, Bernadette Biondi

  • 1Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. dscooper@jhmi.edu

Lancet (London, England)
|January 26, 2012
PubMed
Summary
This summary is machine-generated.

Subclinical thyroid diseases, including mild hyperthyroidism and hypothyroidism, are common but their clinical impact remains unclear. Further research is needed to guide diagnosis and treatment for these thyroid dysfunctions.

Related Experiment Videos

Last Updated: May 25, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Area of Science:

  • Endocrinology
  • Internal Medicine
  • Thyroidology

Background:

  • Subclinical thyroid diseases, characterized by mild thyroid dysfunction, are frequently encountered.
  • The clinical significance and management of subclinical hyperthyroidism and subclinical hypothyroidism are subjects of ongoing debate.

Purpose of the Study:

  • To review the definition, epidemiology, diagnosis, and progression of subclinical thyroid diseases.
  • To discuss the potential health outcomes and management strategies for subclinical thyroid dysfunction.
  • To highlight the need for large-scale randomized trials in this field.

Main Methods:

  • Literature review and synthesis of current evidence on subclinical thyroid diseases.
  • Discussion of diagnostic criteria and risk stratification for progression to overt thyroid disease.
  • Analysis of treatment recommendations based on thyroid-stimulating hormone levels and comorbidities.

Main Results:

  • Subclinical thyroid diseases represent mild thyroid overactivity or underactivity with uncertain clinical implications.
  • Treatment decisions for subclinical thyroid dysfunction depend on the severity of thyroid-stimulating hormone deviation and patient comorbidities.
  • Current evidence is insufficient to definitively guide management, necessitating further research.

Conclusions:

  • Subclinical thyroid diseases are common, but their clinical significance requires further elucidation.
  • Management strategies should consider individual patient factors and the degree of thyroid dysfunction.
  • Large-scale randomized controlled trials are essential to establish optimal care guidelines for subclinical thyroid disease.